WO2001045699A1 - Use of parthenolide to inhibit cancer - Google Patents
Use of parthenolide to inhibit cancer Download PDFInfo
- Publication number
- WO2001045699A1 WO2001045699A1 PCT/US2000/034469 US0034469W WO0145699A1 WO 2001045699 A1 WO2001045699 A1 WO 2001045699A1 US 0034469 W US0034469 W US 0034469W WO 0145699 A1 WO0145699 A1 WO 0145699A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- parthenolide
- cells
- cancer
- paclitaxel
- cell
- Prior art date
Links
- GDOPTJXRTPNYNR-UHFFFAOYSA-N CC1CCCC1 Chemical compound CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- Fatality in cancer is generally due to metastasis and development of resistance to chemotherapy (Fisher, 1994; Liotta et al., 1991). Metastasis and resistance to chemotherapy are mostly due to overexpression of pro-metastatic, pro-angiogenic, multi-drug resistance and anti-apoptotic genes (Baldini, 1997; Fisher, 1994; Wang et al., 1999a).
- NF- ⁇ B Activator Protein
- Ets family of transcription factors (Baeuerle & Henkel, 1994; Grumont et al., 1999; Gutman & Wasylyk, 1990; Lee et al., 1999; Wang et al., 1999b; Wang et al, 1998; Zong et al., 1999).
- interleukin-6 interleukin-6
- urokinase plasminogen activator matrix metalloproteinase 9
- matrix metalloproteinase 9 the pro-angiogenic gene IL-8
- anti-apoptotic genes c-IAPl, cIAP2, TRAF1, TRAF2, Bfl-l/Al, Bcl-X L , and Mn-SOD is induced by NF- ⁇ B (Baeuerle & Henkel, 1994; Grumont et al., 1999; Jones et al., 1997; Lee et al, 1999; Wang et al., 1999b, Wang et al., 1998; Zong et al., 1999).
- NF- ⁇ B Normally, NF- ⁇ B resides in the cytoplasm in an inactive state bound to I ⁇ B proteins (Baeuerle & Henkel, 1994).
- IKC I ⁇ B kinase complex
- NF- ⁇ B dissociates from phosphorylated IKBS, translocates to the nucleus and activates target genes (Baeuerle & Henkel, 1994).
- the ability of activated NF- ⁇ B to induce gene expression depends on the cell type and the type of NF- ⁇ B inducer.
- NF- ⁇ B is inactivated by caspases and the induction of NF- ⁇ B-dependent cell survival signals is markedly reduced (Levkau et al, 1999).
- activation of NF- ⁇ B by growth factors or IL-1 can cause an increase in anti-apoptotic gene expression and subsequent resistance to TNF and chemotherapy (Wang et al., 1996).
- Inhibition of NF- ⁇ B activation by I ⁇ B overexpression can convert TNF- and chemotherapy-resistant cells to a sensitive phenotype (Beg & Baltimore, 1996; Van Antwerp et al., 1996; Wang et al., 1996).
- NF- ⁇ B is constitutively active in a number of tumors including Hodgkin's lymphoma, melanoma, juvenile myelomonocytic leukemia, cutaneous T cell lymphoma, melanoma, squamous cell carcinoma and Bcr-Abl-induced transformation (Bargou et al., 1997; Dong et al., 1999; Giri & Aggarwal, 1998; Reuther et al., 1998; Shattuck-Brandt & Richmond, 1997). Constitutive NF- ⁇ B activation has been described in a subset of breast cancers (Cogswell et al., 2000; Nakshatri et al., 1997; Sovak et al., 1997).
- drugs including aspirin
- aspirin have been described as having some ability to prevent NF- ⁇ B activation (Yin et al., 1998)
- Such drugs can be used as primary or adjunct therapeutic agents in the treatment of cancer, or in other pathologies involving NF- ⁇ B activation.
- the present invention provides a therapeutic method to treat cancer, including hematological malignancies and solid tumors, such as prostate cancer, ovarian cancer, breast cancer, brain cancer and hepatic cancer, comprising administering to a mammal afflicted with said cancer an amount of parthenolide, or an analog thereof that is an NF- ⁇ B inhibitor, effective to inhibit the viability of cancer cells of said mammal.
- the parthenolide may be administered as primary therapy, or as adjunct therapy, either following local intervention (surgery, radiation, local chemotherapy) or in conjunction with at least one other chemotherapeutic agent.
- the present invention also provides a method of increasing the susceptibility of human cancer cells to a chemotherapeutic agent comprising contacting the cells with an effective sensitizing amount of parthenolide.
- the invention provides a therapeutic method for the treatment of a human or other mammal afflicted with cancer, wherein an effective amount of parthenolide is administered to a subject afflicted with said cancer and that may be undergoing, or be about to undergo, treatment with a chemotherapeutic ("antineoplastic") agent.
- chemotherapeutic chemotherapeutic
- the term "parthenolide” includes essentially pure parthenolide, as described below, or analogs exhibiting useful NF- ⁇ B and/or C-IAP2 inhibitory activity that are known or apparent to the art.
- parthenolide is administered in conjunction with one or more chemotherapeutic agents effective against the particular cancer such as gemcitabine or 5-FU, if pancreatic cancer is being treated, tamoxifen or paclitaxel, if breast cancer is to be treated, leuprolide or other anti-androgens, if prostate cancer is involved, and the like.
- the present invention comprises a therapeutic method comprising the administration of parthenolide to treat non-tumorigenic angiogenesis-dependent diseases that are characterized by the abnormal growth of blood vessels.
- Parthenolide may also be utilized in surgical procedures in which anti-angiogenesis is useful, including stent and graft placement and in the treatment of tumor excision sites.
- the present invention also provides a method to determine whether or not a cancer patient will be amenable to treatment by a NF- ⁇ B inhibitor, alone or in combination with one or more other chemotherapeutic agents, comprising (a) isolating a portion of cancer cells from said patient, and (b) determining whether said cells comprise constitutively active NF- ⁇ B and/or express C-IAP2; and correlating the level of NF- ⁇ B and or C-IAP2 with the ability of the inhibitor to inhibit NF- ⁇ B or C-IAP2 in reference cells of said cancer that also comprise NF- KB or C-IAP2.
- This method is based on the fact that a high level of NF- ⁇ B activity and/or overexpression of C-IAP2 is indicative of susceptibility of said cancer cells to a NF- ⁇ B inhibitor.
- a cancer patient about to undergo, or undergoing, treatment for cancer can be rapidly evaluated to see if he/she will benefit from concurrent chemotherapy and administration of parthenolide or an analog thereof.
- high level and “overexpression” are defined by reference to the assays and test data set forth hereinbelow, e.g., a "++" or greater rating on Table 1. For example, it can readily be determined empirically, and by in vitro tests, if a population of cancer cells, such as a population isolated from a cancer patient, exhibits an NF- ⁇ B level or overexpresses the C-IAP2 gene to the extent required to render the cancer susceptible to treatment in accord with the present invention.
- Figure 1 is a graph showing the relative difference in apoptosis among cell types LxSNl 1 and IxB ⁇ SRIO with or without paclitaxel treatment.
- a population of 5 ⁇ 10 4 LxSNl 1 and IxB ⁇ SRIO cells were grown overnight and incubated with paclitaxel for 18 and 48 hrs.
- Apoptosis was measured by ELISA.
- the rate of spontaneous apoptosis in untreated LxSNl 1 cells was set as one unit.
- Figure 2 is a graph depicting the increase in sensitivity of MD231 and HBLIOO breast cancer cells to increasing concentrations of parthenolide, in the presence and absence of 1.0 nM paclitaxel.
- Figure 3 A is a graph depicting the relative apoptosis of HBLIOO cells caused by paclitaxel and/or parthenolide.
- Figure 3B is a photocopy of a Western blot showing PARP cleavage products in HBL 100 cells treated with paclitaxel and/or parthenolide.
- Figure 4A is a photocopy of an EMS A gel showing the effect of parthenolide on NF- ⁇ B binding in prostate cancer cell lines.
- Figure 4B is a graph depicting inhibition of prostate cancer cell inhibition by parthenolide.
- Figure 5 is a graph depicting the inhibition of HUNECs by parthenolide.
- Figure 6 is a graph depicting the inhibition of capillary formation by HUNECs by parthenolide.
- Figure 7 is a graph depicting the effect of parthenolide on in vtvo-induced angiogenesis.
- Figure 8 is a photocopy of an electromobility gel shift assay gel demonstrating the effect of parthenolide on ⁇ F- ⁇ B DNA binding.
- Parthenolide ([laR-(l ⁇ R*, 4E, 7aS*, 10 ⁇ S*, -10bR*)]-2, 3, 6, 7, 7 ⁇ , 8, 10a, lOb-Octahydro-l ⁇ , 5-dimethyl-8-methyleneoxireno[9, 10]cyclodeca[l, 2- b]furan-9(l ⁇ H)-one) or 4,5 ⁇ -epoxy-6 ⁇ -hydroxy-germacra-l(10), l l(13)-dien- 12-oic acid ⁇ -lactone is a sesquiterpene lactone found in feverfew, and in other plants. Its formula is given below:
- Parthenolide is commercially available as 500 meg tablets from Ashbury
- parthenolide has been given to rats and dogs at dosages of from about 250-2500 mg/kg/day without significant toxicity.
- patients can be dosed at 1000 meg/day, and each subsequent cohort will receive a 30% increase in the dose, for two cycles (8 weeks) of therapy at their assigned dose.
- dosages can also be used to treat and develop treatments for other cancers and angiogenesis-dependent conditions, such as those described hereinbelow, as can doses presently used to treat migraine headaches in humans.
- Dosages suitable for human administration can be calculated from dosages effective in animal models as disclosed in U.S. Pat. No. 5,294,430.
- Cancers treatable by the present therapy include the solid and hematological tumors discussed hereinabove, as well as the solid tumors disclosed in U.S. Pat. No. 5,514,555.
- Hematological cancers such as the leukemias are disclosed in the Mayo Clinic Family Health Book. D. E. Larson, ed., William Morrow, NY (1990) and include CLL, ALL, CML and the like.
- methods for inhibiting angiogenesis in patients with non-tumorigenic, angiogenesis- dependent diseases, comprising administering a therapeutically effective amount of a composition comprising parthenolide to a patient with a non-tumorigenic angiogenesis-dependent disease, such that the formation of new blood vessels is inhibited.
- methods are provided for inhibit reactive proliferation of endothelial cells or capillary formation in non-tumorigenic, angiogenesis-dependent diseases, such that the blood vessel is effectively occluded.
- the anti-angiogenic composition comprising parthenolide is delivered to a blood vessel which is actively proliferating and nourishing a tumor.
- Anti-angiogenic parthenolide compositions of the present invention can block the stimulatory effects of angiogenesis promoters, reducing endothelial cell division, decreasing endothelial cell migration, and impairing the activity of the proteolytic enzymes secreted by the endothelium.
- non-tumorigenic angiogenesis-dependent diseases include corneal neovascularization, hypertrophic scars and keloids, proliferative diabetic retinopathy, arteriovenous malformations, atherosclerotic plaques, delayed wound healing, hemophilic joints, nonunion fractures, Osier- Weber syndrome, psoriasis, pyogenic granuloma, scleroderma, trachoma, menorrhagia, retrolental fibroplasia and vascular adhesions.
- the pathology and treatment of these conditions is disclosed in detail in published PCT application PCT/CA94/00373 (WO 95/03036), at pages 26-36.
- Topical or directed local administration of the present compositions is often the preferred mode of administration of therapeutically effective amounts of parthenolide, i.e., in depot or other controlled release forms.
- Anti-angiogenic compositions of the present invention may also be utilized in a variety of other manners.
- they may be incorporated into surgical sutures in order to prevent stitch granulomas, implanted in the uterus (in the same manner as an IUD) for the treatment of menorrhagia or as a form of female birth control, administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis, attached to a monoclonal antibody directed against activated endothelial cells as a form of systemic chemotherapy, or utilized in diagnostic imaging when attached to a radioactively labelled monoclonal antibody which recognizes active endothelial cells.
- a prophylactic or therapeutic dose of parthenolide, an analog thereof or a combination thereof, in the acute or chronic management of cancer will vary with the stage of the cancer, such as the solid tumor to be treated, the chemotherapeutic agent(s) or other anti- cancer therapy used, and the route of administration.
- the dose, and perhaps the dose frequency will also vary according to the age, body weight, and response of the individual patient.
- the total daily dose range for parthenolide and its analogs, for the conditions described herein is from about 0.5 mg to about 2500 mg, in single or divided doses.
- a daily dose range should be about 1 mg to about 100 mg, in single or divided doses, most preferably about 5-50 mg per day.
- the therapy should be initiated at a lower dose and increased depending on the patient's global response. It is further recommended that infants, children, patients over 65 years, and those with impaired renal or hepatic function initially receive lower doses, and that they be titrated based on global response and blood level. It may be necessary to use dosages outside these ranges in some cases. Further, it is noted that the clinician or treating physician will know how and when to interrupt, adjust or terminate therapy in conjunction with individual patient response.
- the terms "an effective amount” or “an effective sensitizing amount” are encompassed by the above-described dosage amounts and dose frequency schedule.
- any suitable route of administration may be employed for providing the patient with an effective dosage of parthenolide. While it is possible that, for use in therapy, parthenolide or its analogs may be administered as the pure chemicals, as by inhalation of a fine powder via an insufflator, it is preferable to present the active ingredient as a pharmaceutical formulation.
- the invention thus further provides a pharmaceutical formulation comprising parthenolide or an analog thereof, together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients.
- the carrier(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof, such as a human patient or domestic animal.
- compositions include those suitable for oral or parenteral (including intramuscular, subcutaneous and intravenous) administration.
- Forms suitable for parenteral administration also include forms suitable for administration by inhalation or insufflation or for nasal, or topical (including buccal, rectal, vaginal and sublingual) administration.
- the formulations may, where appropriate, be conveniently presented in discrete unit dosage forms and may be prepared by any of the methods well known in the art of pharmacy.
- Such methods include the step of bringing into association the active compound with liquid carriers, solid matrices, semi-solid carriers, finely divided solid carriers or combinations thereof, and then, if necessary, shaping the product into the desired delivery system.
- Pharmaceutical formulations suitable for oral administration may be presented as discrete unit dosage forms such as hard or soft gelatin capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or as granules; as a solution, a suspension or as an emulsion; or in a chewable base such as a synthetic resin or chicle for ingestion of the agent from a chewing gum.
- the active ingredient may also be presented as a bolus, electuary or paste.
- Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents.
- the tablets may be coated according to methods well known in the art, i.e., with enteric coatings.
- Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), or preservatives.
- the compounds according to the invention may also be formulated for parenteral administration (e.g., by injection, for example, bolus injection or continuous infusion) and may be presented in unit dose form in ampules, pre- filled syringes, small volume infusion containers or in multi-dose containers with an added preservative.
- the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.
- the compounds may be formulated as ointments, creams or lotions, or as the active ingredient of a transdermal patch.
- Suitable transdermal delivery systems are disclosed, for example, in A. Fisher et al. (U.S. Patent No. 4,788,603), or R. Bawa et al. (U.S. Patent Nos. 4,931,279; 4,668,506 and 4,713,224).
- Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
- Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
- Formulations suitable for topical administration in the mouth include unit dosage forms such as lozenges comprising active ingredient in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; mucoadherent gels, and mouthwashes comprising the active ingredient in a suitable liquid carrier.
- unit dosage forms such as lozenges comprising active ingredient in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; mucoadherent gels, and mouthwashes comprising the active ingredient in a suitable liquid carrier.
- the above-described formulations can be adapted to give sustained release of the active ingredient employed, e.g., by combination with certain hydrophilic polymer matrices, e.g., comprising natural gels, synthetic polymer gels or mixtures thereof.
- the polymer matrix can be coated onto, or used to form, a medical prosthesis, such as a stent, valve, shunt, graft, or the like.
- compositions suitable for rectal administration wherein the carrier is a solid are most preferably presented as unit dose suppositories.
- Suitable carriers include cocoa butter and other materials commonly used in the art, and the suppositories may be conveniently formed by admixture of the active compound with the softened or melted carrier(s) followed by chilling and shaping in molds.
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing, in addition to the active ingredient, such carriers as are known in the art to be appropriate.
- the compounds according to the invention are conveniently delivered from an insufflator, nebulizer or a pressurized pack or other convenient means of delivering an aerosol spray.
- Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- the compounds according to the invention may take the form of a dry powder composition, for example, a powder mix of the compound and a suitable powder base such as lactose or starch.
- the powder composition may be presented in unit dosage form in, for example, capsules or cartridges or, e.g., gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.
- the compounds of the invention may be administered via a liquid spray, such as via a plastic bottle atomizer. Typical of these are the Mistometer ® (Wintrop) and the Medihaler ® (Riker).
- the compounds can be administered as drops, gels (see, S. Chrai et al., U.S. Patent No. 4,255,415), gums (see S.-L. Lin et al., U.S. Patent No. 4,136,177) or via a prolonged-release ocular insert.
- I ⁇ B ⁇ super-repressor I ⁇ B ⁇ SR plasmid containing S32A and S36A mutation of I ⁇ B ⁇ was generated by PCR mediated site-directed mutagenesis and cloned into the EcoRI site of the modified retro virus vector LxSN (Miller & Rosman, 1989; Wang et al., 1996). Retrovirus and stable I ⁇ B ⁇ SR expressing MDA-MB-231 clones were prepared as described previously (Newton et al., 1999).
- Electrophoretic Mobility Shift Assays Whole cell extracts were prepared and subjected to EMS A with NF- ⁇ B and SP-1 probes (Promega, Madison, WI) (Newton et al., 1999). Nuclear extracts were prepared as described previously (Dignam et al., 1983). Antibodies for supershift assays were purchased from Santa Cruz Biotechnology (CA) or Upstate Biotechnology (NY).
- Cell Death Assays Apoptosis Assay and PARP Cleavage.
- 2 x 10 3 cells grown overnight on a 96-well plate were treated with paclitaxel and/or parthenolide (dissolved in ethanol). In combination treatment, parthenolide was added 4 h before paclitaxel treatment. Cell death was measured 18 h after paclitaxel treatment using the MTS assay (Promega, Madison, WI). Apoptosis was measured by a histone-ELISA (Roche Diagnostics, Indianapolis, IN). 5 x 10 4 cells grown overnight on six well plates were treated with paclitaxel for indicated times. Histone-DNA complexes in the supernatant were detected by ELISA.
- Table 1 Summary of NF- ⁇ B DNA binding activity, C-IAP2 and
- Mn-SOD expression in breast cancer cell lines has been described (Newton et al., 1999). Relative expression of c- IAP2 and Mn-SOD was calculated by densitometric scanning of autoradiograms.
- MCF-7, T47D and ZR-75-1 cells are estrogen receptor alpha (ER ⁇ )-positive (Sommers et al, 1994).
- ER ⁇ estrogen receptor alpha
- Sommers et al, 1994 transcriptional activity but not DNA binding activity of NF- ⁇ B is inhibited by ER ⁇ (Galien & Garcia, 1997; Nakshatri et al., 1997).
- ER ⁇ -negative breast cancer cells with higher levels of constitutive NF- ⁇ B DNA binding activity may overexpress NF- ⁇ B-inducible genes compared to ER ⁇ -positive breast cancer cells.
- RNase protection assays Northern analysis, cDNA microarray and differential display methods were used to identify NF- ⁇ B regulated genes in breast cancer cells.
- the RNase protection assay was performed with hAPO-5 probe, which allows quantitation of xIAP, TRAFl, TRAF2, CART, NIAP, c-IAPl, C-IAP2, TRPM2 and CRAF genes.
- xIAP, TRAFl, TRAF2, c-IAPl, C-IAP2 and NIAP are anti-apoptotic (Deveraux & Reed, 1999; Wang et al., 1998).
- TRPM-2 is anti-apoptotic in certain cell types (Miyake et al., 2000).
- xIAP, CART1 and CARP There was no significant variation in the expression levels of xIAP, CART1 and CARP among various cell types.
- C-IAP2 expression was observed only in MDA-MB-231, MDA-MB-436, MDA-MB-468 and HBLIOO cells, all of which contain high levels of constitutive NF- ⁇ B DNA binding activity as shown in Table 1.
- the C-IAP2 expression in these cells was further confirmed by Northern blot analysis (data not shown). TRAFl expression was observed in MDA-MB- 231 and MDA-MB-436 cells. Cell type-specific variation in TRPM2 expression was observed but did not correlate with NF- ⁇ B DNA binding activity.
- the expression levels of the anti-apoptotic gene c-IAPl, Mn-SOD and survivin were measured by Northern blotting (Jones et al., 1997; Li et al., 1998; Wang et al., 1998). While all cell lines expressed similar levels of c-IAPl and survivin, Mn- SOD expression was higher in ER ⁇ -negative breast cancer cells with constitutive NF- ⁇ B DNA binding activity. Increased expression of Mn-SOD in ER ⁇ - negative breast cancer cells was further confirmed by Western blotting.
- Mn-SOD. TRAFl and DAD-1 Expression in MDA-MB-231 Cells To further investigate whether C-IAP2 and Mn-SOD expression is dependent on NF- ⁇ B, MDA-MB-231 cells overexpressing I ⁇ B ⁇ SR were generated. Approximately 50% of colonies isolated using neornycin/G418 as a selection marker expressed I ⁇ B ⁇ SR. Most of these clones lost I ⁇ B ⁇ SR expression after continuous propagation in culture. No clones were obtained that were completely devoid of constitutive NF- ⁇ B DNA binding activity.
- I ⁇ B ⁇ SR6, 8 and 10 Three clones expressing I ⁇ B ⁇ SR (I ⁇ B ⁇ SR6, 8 and 10) and a clone containing retrovirus vector alone (LxSNl 1) were used for further studies. Constitutive NF- ⁇ B DNA activity in these clones was measured by EMSA using the general transcription factor SP-1 as an internal control. I ⁇ B ⁇ SR6, I ⁇ B ⁇ SR8 and I ⁇ B ⁇ SR10 cells displayed 20, 10 and 40% lower NF- ⁇ B DNA binding activity, respectively, than LxSNl 1 cells.
- Apoptosis by chemotherapeutic agents including paclitaxel involves activation of caspase 9 and caspase 3 (Thornberry & Lazebnik, 1998). Anti- apoptotic function of NF- ⁇ B is mostly due to Mn-SOD and C-IAP2 mediated inhibition of caspase 9 activation (Deveraux & Reed, 1999; Green & Reed, 1998). Also C-IAP2 inhibits the activity of caspase 3 (Deveraux & Reed, 1999). Recent studies have indicated that NF- ⁇ B alters cell cycle progression by modulating the expression of cell cycle regulatory genes (Guttridge et al., 1999; Hinz et al., 1999). Based on these observations, constitutively active NF- ⁇ B may decrease the sensitivity of cancer cells to chemotherapeutic agents whose activity is cell cycle-dependent.
- paclitaxel was chosen for further study because of a consistent difference in response of LxSNl 1 and I ⁇ B ⁇ SR cells to this drug.
- Paclitaxel is a microtubule-stabilizing agent whose action is concentration dependent (Torres & Horwitz, 1998). At ⁇ 9 nM drug concentration, paclitaxel acts by retarding or inhibiting progression through mitosis, thus altering microtubule dynamics. At these concentrations, cells exit mitosis aberrantly and fractionate into hypodiploid populations during cell cycle analysis (Torres & Horwitz, 1998).
- paclitaxel increases microtubule polymer mass, terminal G2/M arrest and cell death with a concomitant decrease in hypodiploid cells (Torres & Horwitz, 1998).
- 3 nM paclitaxel concentration approximately 30% of all cell types were hypodiploid. Hypodiploid population from all three cell types formed similar numbers of colonies when grown in culture suggesting that hypodiploid population not always represent apoptotic cells (data not shown).
- Increasing paclitaxel concentration to 5 nM did not alter the cell cycle distribution pattern of LxSNl 1 cells. In contrast, a large percent of I ⁇ B ⁇ SR cells were arrested at G2/M phase of the cell cycle.
- the percentage of cells at G2/M were 28.45 ⁇ 4.05, 70.37 ⁇ 14.9 and 62.1 ⁇ 13.1% for LxSNl 1, I ⁇ B ⁇ SR6 and I ⁇ B ⁇ SR10 cells, respectively. Only diploid cells were considered while calculating the percentage of cells in different phases of the cell cycle.
- Table 2 The effect of paclitaxel on cell cycle progression of wild type and p65-7- fibroblasts. Cells were treated with indicated concentration of paclitaxel and cell cycle distribution was measured after 18 h of treatment. Consistent with this possibility, paclitaxel caused G2/M arrest of several other breast cancer cell lines (data not shown).
- InM 68 ⁇ 4 20 ⁇ 4 17 -: 8 47 ⁇ 2 53 ⁇ 1 -
- Parthenolide Inhibits NF- ⁇ B DNA Binding Activity and Increases the Sensitivity of Breast Cancer Cells to Paclitaxel
- Curcumin, N-acetyl cysteine, pentoxyphylline, parthenolide, epigallocatechin gallate, Bay 11-7085 or MG-132 were evaluated for their ability to inhibit NF- ⁇ B DNA binding activity in breast cancer cells (Biswas et al., 1993; Hehner et al., 1998; Kumar et al., 1998; Lin et al., 1998; Pierce et al., 1997; Yang et al., 1998). Only parthenolide, MG132 and Bay 11-7085 inhibited NF- ⁇ B DNA binding activity in MDA-MB-231 cells.
- MDA-MB-231 cells were incubated with increasing concentrations (1, 2 and 5 ⁇ M) of parthenolide for 3 h.
- Whole cell extracts or nuclear extracts (5 ⁇ M only) from untreated and treated cells were subjected to EMSA with NF- ⁇ B or SP-1 probe.
- Parthenolide also inhibited constitutive NF- ⁇ B DNA binding activity in HBLIOO cells (data not shown).
- the effect of parthenolide on NF- ⁇ B DNA binding activity in cells treated with paclitaxel was then investigated.
- MDA-MB-231 cells pretreated with 5 ⁇ M parthenolide for 1 h were exposed to 50 nM paclitaxel for 1 h.
- EMSA was performed with whole cell extracts using NF- ⁇ B probe or SP-1 probe.
- paclitaxel has been shown to induce NF- ⁇ B in other cell types (Das & White, 1997), untreated and paclitaxel-treated MDA-MB-231 cells displayed a similar level of NF- ⁇ B DNA binding activity. Nonetheless, parthenolide inhibited NF- ⁇ B DNA binding activity in paclitaxel-treated cells.
- MDA-MB-231 and HBLIOO cells were exposed to increasing concentrations of either paclitaxel or parthenolide and cell survival was measured after 18 h by an MTS assay.
- Half-maximal growth-inhibitory concentration (IC 50 ) was reached at 10 nM and 0.8 ⁇ M for paclitaxel and parthenolide, respectively, in HBLIOO cells (data not shown).
- Apoptosis in paclitaxel treated cells was set as 10 units and relative apoptosis in cells treated with either parthenolide alone or both paclitaxel and parthenolide is shown. Paclitaxel alone induced apoptosis to a certain degree whereas parthenolide was ineffective
- PARP cleavage product was detected when cells were treated with a combination of 5 nM paclitaxel and 0.5 ⁇ M parthenolide.
- PARP cleavage was not detected in cells treated with low concentrations of paclitaxel and parthenolide, although cell death at these concentrations was measurable in MTS assays. This discrepancy is most likely due to differences in the sensitivity of the two assays. Nevertheless, these results suggest that inhibition of NF- ⁇ B activity by parthenolide increases the rate of apoptotic cell death by paclitaxel.
- constitutive NF- ⁇ B DNA binding activity in breast cancer cells correlates with increased expression of the anti- apoptotic genes C-IAP2 and Mn-SOD. Also, constitutive NF- ⁇ B DNA binding has been shown to correlate with increased expression of the pro-metastatic genes urokinase plasminogen activator, IL-6 and IL-8 (Newton et al., 1999). These observations are significant because constitutive NF- ⁇ B DNA binding has been observed in 65% of primary breast cancers (Sovak et al., 1997).
- C-IAP2 is a major NF- ⁇ B inducible gene in breast cancer cells.
- C-IAP2 is a more potent inhibitor of caspase 3 and caspase 7 activity than c-IAPl, and can suppress apoptosis induced by a variety of stimuli including TNF, Fas, menadione, staurosporine, etoposide, paclitaxel and growth factor withdrawal (Deveraux & Reed, 1999).
- Bax activates caspase-dependent and caspase-independent apoptotic pathways (Xiang et al., 1996).
- Constitutively active NF- ⁇ B through C-IAP2 may confer chemoresistance even in tumors that express Bax, because C-IAP2 can block the caspase-dependent apoptotic pathway (Deveraux & Reed, 1999).
- Paclitaxel is a commonly used chemotherapeutic agent in both the adjuvant and metastatic settings.
- C-IAP2 expression can provide a predictor of response to this important agent and its analogs.
- Mn-SOD appears to have a dual role in cancer. Mn-SOD can reduce oxidative stress, protect against DNA damage and prevent initiation of cancerous mutation (Oberley & Oberley, 1997). Consistent with this possibility, the incidence of breast cancer is higher in premenopausal women who have inherited the polymorphic variant of Mn-SOD with reduced biological activity (Ambrosone et al., 1999). However, Mn-SOD may also protect cancer cells from chemotherapy induced oxidative stress and apoptosis (Manna et al., 1998).
- Mn-SOD overexpression of Mn-SOD alone is sufficient to confer resistance to okadaic acid, H 2 O 2 , and paclitaxel but not vincristine, vinblastine and daunomycin induced apoptosis of breast cancer cells (Manna et al., 1998).
- NF- ⁇ B may also have a dual role in mammary epithelial cells.
- Mn-SOD and other anti-oxidant genes By upregulating Mn-SOD and other anti-oxidant genes, NF- ⁇ B may protect normal mammary epithelial cells from oxidative stress and DNA damage. In cancer cells, however, these anti-oxidant gene products may protect against chemotherapy induced oxidative stress and apoptosis.
- NF- ⁇ B can protect against chemotherapeutic agents if it is constitutively active and, as a consequence, cells constitutively express Mn-SOD and C-IAP2.
- I ⁇ B ⁇ SR or NF- ⁇ B inhibitors may be useful in overcoming chemotherapeutic resistance of only those cells that contain constitutively active NF- ⁇ B. Consistent with this possibility, I ⁇ B ⁇ SR overexpression in HPB, HCT116, MCF-7, and OVCAR-3 cells, all of which lack constitutively active NF- ⁇ B, did not increase the sensitivity to paclitaxel (Bentires-Aji et al., 1999).
- parthenolide can function similarly to I ⁇ B ⁇ SR by increasing the sensitivity of breast cancer cells to paclitaxel.
- the degree of synergism appears to be dependent on the cell type, as HBLIOO cells were more sensitive to the combined treatment than MDA-MB-231 cells.
- the cell type-specific effect may be related to differences in the stability of parthenolide within cells or the number of cell survival pathways that are active in a particular cell type.
- NF- ⁇ B-mediated survival pathway is believed to be the major cell survival pathway in HBLIOO cells, whereas NF- ⁇ B-independent survival pathways provide partial protection to MDA-MB-231 cells.
- MDA-MB-231 cells represent a more "advanced cancer cell type" (with respect to growth in nude mice) than HBLIOO cells (Price et al., 1990; Sommers et al., 1994).
- a combination of parthenolide and chemotherapeutic drugs may be beneficial. Such an approach is less likely to be toxic to normal cells.
- Parthenolide Inhibits Prostate Cancer Cell Proliferation
- Two prostate cancer cell lines (hormone sensitive, LNCaP and hormone- resistant PC-3) were cultured and treated with 0.5, 1.0, 2.5 and 5 ⁇ M parthenolide.
- Mobility shift gel electrophoresis assay was performed on the prostate cancer cells after treatment with parthenolide for three hours.
- Proliferation assays were performed using a 96 well plate with cell viability assesses utilizing the MTS/PMS assay (see Example 6). Inhibition was compared with a solvent control.
- NF- ⁇ B is constitutively active in both a hormone-sensitive and hormone- resistant prostate cancer cell line.
- the greater binding in the hormone-resistant cell line suggests that this transcription factor may be involved in the development of hormone resistance.
- Inhibition of this transcription factor with parthenolide results in an inhibition of prostate cancer cell proliferation.
- HUNECs Human umbilical venous endothelial cells
- EGM-2 media Clonetics, San Diego, CA
- Parthenolide powder Sigma Chemical Co., St. Louis, MO
- RhuMAb VEGF provided by Genentech, South San Francisco, CA was used in the electromobihty gel shift assay.
- VEGF vascular endothelial growth factor
- bFGF basic Fibroblast Growth Factor
- Thrombin, bovine fibrinogen and aprotinin were used for the formation of a fibrin clot.
- Microcarrier beads consisting of thin layer denatured collagen chemically coupled to a matrix of cross-linked dextran (175 microns, Cytodex TM 3, Amersham Pharmacia, Biotech AB, Uppsale, Sweden) were employed as the base for the capillary formation. This assay has been shown to induce capillaries with identifiable lumens.
- the MTS/PMS system Promega, Madison, WI was used to assess cell viability for the proliferation assay.
- HUNECs were plated in a 96-well U-bottomed plate (Becton Dickinson Labware, Franklin Lakes, ⁇ J) at a concentration of 10,000 cells per 50 microliters ( ⁇ L) of media and incubated in 5% CO 2 at 37°C for 48 hours.
- Varying drug concentrations in 50 ⁇ L of media were added to the media and this mixture was added to each well within one hour of the HUNECs being seeded.
- the proliferation experiments were performed with and without stimulation by the addition of NEGF (60 ng/mL) and bFGF (20 ng/mL). These factors in high doses were chosen to partially simulate the tumor microenvironment.
- Endothelial cell capillary formation Two hundred milligrams of microcarrier beads suspended in PBS were autoclaved and then added to HUNECs at a concentration of 30 HUNECs per microcarrier bead. Microcarrier beads and cells were added to a siliconized petri dish and rocked at 37°C in 5% CO 2 for 48 hours. The HUNEC coated microcarrier beads were transferred to a fibrin clot solution. Fibrinogen was dissolved at 2.5 mg/mL in PBS with 0.15 U/mL of aprotinin. Approximately 20 HUNEC coated microcarrier beads were added to each well of a 12 well plate and then thrombin (0.625 U/mL) was added to form a gelatinous clot.
- HUVECs were plated on 100 mm plates and harvested in an exponential growth phase. Drugs, antibodies and cytokines were added three hours prior to harvesting - bFGF alone at 50 ng/mL, VEGF alone at 100 ng/mL, rhuMAb VGEF at 10 mg/mL, bFGF plus rhuMAb VEGF; VEGF plus rhuMAb VEGF and parthenolide at doses ranging from 2 to 10 ⁇ M.
- Cellular extracts were made and incubated with a radiolabelled ⁇ F- ⁇ B probe for 30 minutes at 25°C. This protein probe binds to the NF- ⁇ B DNA binding site in the promoter region of the immunoglobulin gene.
- the mixture was then electrophoresed. Specific NF- ⁇ B binding to DNA was identified by the presence of a signal seen at autoradiography. The protein-DNA complex was slower to migrate whereas unbound DNA and protein migrated off the gel. The specificity of the drug inhibiting NF- ⁇ B DNA binding was verified by the use of the SP-1 probe as a control.
- Matrigel Plug Assay Matrigel was prepared on ice and incubated with 100 ng/mL of VEGF or
- mice 50 ng/mL of bFGF. Under light anaesthesia with isofluorane, 0.3 mL of matrigel was injected into the left and right flanks of each mouse. The VEGF containing matrigel plug was placed on the left and the bFGF plug was placed on the right. On the second day after the plugs were inserted, the mice were treated daily for 14 days by oral gavage. Parthenolide was dissolved in 100% alcohol at 40 mg/mL and then diluted in PBS so that each mouse received their assigned dose in 100 ⁇ L of solution. There were 10 mice per cohort and the treatments were (1) 20% alcohol in PBS - control; (2) 0.4 mg/mL; (3) 4.0 mg/mL and 40 mg/mL.
- mice were sacrificed and the plugs harvested on the 14 th day.
- the hemoglobin content was measured using the "Drabkins assay”.
- the weight of each plug was determined and the plugs were dissolved in 100 ml of water per mg of matrigel plug.
- the mixture was placed in duplicate in a 96 well plate and incubated for 24 hours.
- the optical density was determined and the average for each pair was determined.
- the optical density is a measure of the hemoglobin content and the median for each cohort was determined with the standard error also calculated.
- bFGF induced greater DNA binding than VEGF.
- the bFGF effect was not altered by rhuMAb- VEGF.
- RhuMAb-VEGF did not alter NF- ⁇ B DNA binding.
- VEGF did not alter baseline NF- ⁇ B DNA binding.
- Parthenolide was able to markedly decrease but not eliminate the NF- ⁇ B DNA binding at baseline at 2 ⁇ M and 4 ⁇ M. At doses of 6 ⁇ M and higher, there was complete inhibition of DNA binding.
- Angiogenesis has been found to be a critical factor in many physiological processes such as embryonic development and wound healing as well as in pathological processes, which include the neovascularity that can cause blindness in diabetic retinopathy and the induction of a new blood supply to support the growth of cancerous growth. Inhibition of the latter process by anti- angiogenic agents has been shown to induce tumor regression.
- One such agent is rhuMAb VEGF which can induce tumor regression in 20%o of patients with breast cancer.
- the data presented in this example demonstrates that actively proliferating venous endothelial cells have constitutive NF- ⁇ B DNA binding.
- parthenolide may be a potent anti-angiogenic agent for the treatment of angiogenic-based diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002406733A CA2406733A1 (en) | 1999-12-23 | 2000-12-19 | Use of parthenolide to inhibit cancer |
EP00988155A EP1242071A4 (en) | 1999-12-23 | 2000-12-19 | Use of parthenolide to inhibit cancer |
AU24392/01A AU780573B2 (en) | 1999-12-23 | 2000-12-19 | Use of parthenolide to inhibit cancer |
US10/178,054 US6890946B2 (en) | 1999-12-23 | 2002-06-21 | Use of parthenolide to inhibit cancer |
US11/063,144 US20050143451A1 (en) | 1999-12-23 | 2005-02-22 | Use of parthenolide to inhibit cancer |
AU2005202984A AU2005202984B2 (en) | 1999-12-23 | 2005-07-07 | Use of parthenolide to inhibit cancer |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17302399P | 1999-12-23 | 1999-12-23 | |
US17302499P | 1999-12-23 | 1999-12-23 | |
US60/173,024 | 1999-12-23 | ||
US60/173,023 | 1999-12-23 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/178,054 Continuation US6890946B2 (en) | 1999-12-23 | 2002-06-21 | Use of parthenolide to inhibit cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001045699A1 true WO2001045699A1 (en) | 2001-06-28 |
Family
ID=26868708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/034469 WO2001045699A1 (en) | 1999-12-23 | 2000-12-19 | Use of parthenolide to inhibit cancer |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1242071A4 (en) |
AU (2) | AU780573B2 (en) |
CA (1) | CA2406733A1 (en) |
WO (1) | WO2001045699A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002040017A1 (en) * | 2000-11-15 | 2002-05-23 | National University Of Singapore | Cancer chemotherapeutical and chemopreventive agent |
WO2002053138A2 (en) * | 2001-01-02 | 2002-07-11 | Elisabeth Shanahan-Prendergast | Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens |
EP1297832A2 (en) * | 2001-09-26 | 2003-04-02 | Mark Zamoyski | Composition and methods for treating psoriasis |
EP1297831A2 (en) * | 2001-09-26 | 2003-04-02 | Mark Zamoyski | Compositions and methods for epidermal chemexfoliation |
WO2004043476A1 (en) * | 2002-11-05 | 2004-05-27 | Gelstat Corporation | Compositions and methods of treatment to alleviate or prevent migrainous headaches and their associated symptoms |
WO2004043477A1 (en) * | 2002-11-05 | 2004-05-27 | Gelstat Corporation | Dietary supplement comprising parthenolide |
WO2004112819A1 (en) * | 2003-06-13 | 2004-12-29 | Gelstat Corporation | Compositions and methods of treatment comprising plant extracts |
EP1496880A2 (en) * | 2002-04-24 | 2005-01-19 | Research Development Foundation | SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-kB INHIBITORS AND ANTI-NEOPLASTIC AGENTS |
WO2005007103A2 (en) | 2003-07-11 | 2005-01-27 | University Of Kentucky Research Foundation | Use of parthenolide derivatives as antileukemic and cytotoxic agents |
WO2008007450A1 (en) * | 2006-07-14 | 2008-01-17 | Mmt Co., Ltd. | Food, drink and medicinal composition having antitumor effect |
US7678904B2 (en) | 2003-07-11 | 2010-03-16 | University Of Kentucky | Use of parthenolide derivatives as antileukemic and cytotoxic agents |
WO2013071066A1 (en) * | 2011-11-11 | 2013-05-16 | The Broad Institute, Inc. | Signatures associated with the response to cancer therapy |
WO2022217878A1 (en) * | 2021-04-13 | 2022-10-20 | 广东唯泰生物科技有限公司 | Preparation method and recovery method for pariduval mesenchymal stem cells |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2141126A1 (en) * | 1995-01-26 | 1996-07-27 | Natalie J. Lazarowych | Combinational drug for treating migraine and other illnesses |
AU1573499A (en) * | 1997-12-23 | 1999-07-19 | Moser, Rene | Sesquiterpene lactones specifically inhibit activation of nf-k B by preventing the degradation of IkB-alpha and IkB-beta |
-
2000
- 2000-12-19 WO PCT/US2000/034469 patent/WO2001045699A1/en active IP Right Grant
- 2000-12-19 CA CA002406733A patent/CA2406733A1/en not_active Abandoned
- 2000-12-19 AU AU24392/01A patent/AU780573B2/en not_active Ceased
- 2000-12-19 EP EP00988155A patent/EP1242071A4/en not_active Withdrawn
-
2005
- 2005-07-07 AU AU2005202984A patent/AU2005202984B2/en not_active Ceased
Non-Patent Citations (19)
Title |
---|
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 226, no. 3, 1996, pages 810 - 818 * |
DATABASE CA [online] AMERICAN CHEMICAL SOCIETY; HEHNER S.P. ET AL.: "Sesquiterpene lactones specifically inhibit activation of NF-kappaB by preventing the degradation of IkappaB-alpha and IkappaB-beta", XP002938243, accession no. STN Database accession no. 128:200703 * |
DATABASE CA [online] AMERICAN CHEMICAL SOCIETY; HEHNER S.P. ET AL.: "The antiinflammatory sesquiterpene lactone parthenolide inhibits NG-kappaB by targeting the IkappaB kinase complex", XP002938241, accession no. STN Database accession no. 132:44670 * |
DATABASE CA [online] AMERICAN CHEMICAL SOCIETY; HWANG D. ET AL.: "Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases", XP002938245, accession no. STN Database accession no. 125:273221 * |
DATABASE CA [online] AMERICAN CHEMICAL SOCIETY; ROSS J.J. ET AL.: "Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion", XP002938242, accession no. STN Database accession no. 130:232122 * |
DATABASE CA [online] AMERICAN CHEMICAL SOCIETY; WIEDHOPF R.M. ET AL.: "Tumor inhibitory agent from Magnolia grandiflora (Magnoliaceae). I. Parthenolide", XP002938247, accession no. STN Database accession no. 78:115152 * |
DATABASE CA [online] AMERICAN CHEMICAL SOCIETY; WOYNAROWSKI J.M. ET AL.: "Inhibition of DNA biosynthesis in HeLa cells by cytotoxic and antitumor sesquiterpene lactones", XP002938246, accession no. STN Database accession no. 94:150059 * |
DATABASE DERWENT DRUG FILE [online] DERWENT INFORMATION LIMITED; BORK P.M. ET AL.: "Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NG-kappaB", XP002938244, accession no. STN Database accession no. 1997-09449 * |
FEBS LETT., vol. 402, no. 1, 1997, pages 85 - 90 * |
J. BIOL. CHEM., vol. 273, no. 3, 1998, pages 1288 - 1297 * |
J. IMMUNOL., vol. 163, no. 10, 1999, pages 5617 - 5623 * |
J. PHARM. SCI., vol. 62, no. 2, 1973, pages 345 * |
MOL. PHARMACOL., vol. 19, no. 1, 1981, pages 97 - 102 * |
MONDRANONDRA ET AL., PHARMACEUTICAL RESEARCH, vol. 7, 1990, pages 1269 - 1272 |
PLANTA MED., vol. 65, no. 2, 1999, pages 126 - 129 * |
ROSS ET AL., PLANTA MEDICA, vol. 65, 1999, pages 126 - 129 |
See also references of EP1242071A4 * |
WIEDHOPF ET AL., JOURNAL OF PHARMACOLOGICAL SCIENCES, vol. 62, 1973, pages 345 |
WOYNAROWSKI; KONOPA, MOLECULAR PHARMACOLOGY, vol. 19, 1981, pages 97 - 102 |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002040017A1 (en) * | 2000-11-15 | 2002-05-23 | National University Of Singapore | Cancer chemotherapeutical and chemopreventive agent |
WO2002053138A2 (en) * | 2001-01-02 | 2002-07-11 | Elisabeth Shanahan-Prendergast | Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens |
WO2002053138A3 (en) * | 2001-01-02 | 2002-09-19 | Elisabeth Shanahan-Prendergast | Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens |
EP1297832A2 (en) * | 2001-09-26 | 2003-04-02 | Mark Zamoyski | Composition and methods for treating psoriasis |
EP1297831A2 (en) * | 2001-09-26 | 2003-04-02 | Mark Zamoyski | Compositions and methods for epidermal chemexfoliation |
EP1297832A3 (en) * | 2001-09-26 | 2003-04-16 | Mark Zamoyski | Composition and methods for treating psoriasis |
EP1297831A3 (en) * | 2001-09-26 | 2003-04-16 | Mark Zamoyski | Compositions and methods for epidermal chemexfoliation |
EP1496880A2 (en) * | 2002-04-24 | 2005-01-19 | Research Development Foundation | SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-kB INHIBITORS AND ANTI-NEOPLASTIC AGENTS |
EP1496880A4 (en) * | 2002-04-24 | 2007-12-12 | Res Dev Foundation | SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-kB INHIBITORS AND ANTI-NEOPLASTIC AGENTS |
WO2004043476A1 (en) * | 2002-11-05 | 2004-05-27 | Gelstat Corporation | Compositions and methods of treatment to alleviate or prevent migrainous headaches and their associated symptoms |
US7192614B2 (en) | 2002-11-05 | 2007-03-20 | Gelstat Corporation | Compositions and methods of treatment to alleviate or prevent migrainous headaches and their associated symptoms |
WO2004043477A1 (en) * | 2002-11-05 | 2004-05-27 | Gelstat Corporation | Dietary supplement comprising parthenolide |
WO2004112819A1 (en) * | 2003-06-13 | 2004-12-29 | Gelstat Corporation | Compositions and methods of treatment comprising plant extracts |
US7678904B2 (en) | 2003-07-11 | 2010-03-16 | University Of Kentucky | Use of parthenolide derivatives as antileukemic and cytotoxic agents |
US8716329B2 (en) | 2003-07-11 | 2014-05-06 | University Of Kentucky | Use of parthenolide derivatives as antileukemic and cytotoxic agents |
US10251890B2 (en) | 2003-07-11 | 2019-04-09 | University Of Kentucky | Use of parthenolide derivatives as antileukemic and cytotoxic agents |
EP1643984A4 (en) * | 2003-07-11 | 2009-01-07 | Univ Kentucky Res Found | Use of parthenolide derivatives as antileukemic and cytotoxic agents |
US9447112B2 (en) | 2003-07-11 | 2016-09-20 | University Of Kentucky | Use of parthenolide derivatives as antileukemic and cytotoxic agents |
WO2005007103A2 (en) | 2003-07-11 | 2005-01-27 | University Of Kentucky Research Foundation | Use of parthenolide derivatives as antileukemic and cytotoxic agents |
AU2004257696B2 (en) * | 2003-07-11 | 2010-09-16 | University Of Kentucky Research Foundation | Use of parthenolide derivatives as antileukemic and cytotoxic agents |
US8124652B2 (en) | 2003-07-11 | 2012-02-28 | University Of Kentucky | Use of parthenolide derivatives as antileukemic and cytotoxic agents |
US9045490B2 (en) | 2003-07-11 | 2015-06-02 | University Of Kentucky | Use of parthenolide derivatives as antileukemic and cytotoxic agents |
US8470875B2 (en) | 2003-07-11 | 2013-06-25 | University Of Kentucky | Use of parthenolide derivatives as antileukemic and cytotoxic agents |
EP1643984A2 (en) * | 2003-07-11 | 2006-04-12 | University of Kentucky Research Foundation | Use of parthenolide derivatives as antileukemic and cytotoxic agents |
JPWO2008007450A1 (en) * | 2006-07-14 | 2009-12-10 | 株式会社エム・エム・ティー | Food / drink and pharmaceutical composition having tumor suppressive action |
WO2008007450A1 (en) * | 2006-07-14 | 2008-01-17 | Mmt Co., Ltd. | Food, drink and medicinal composition having antitumor effect |
WO2013071066A1 (en) * | 2011-11-11 | 2013-05-16 | The Broad Institute, Inc. | Signatures associated with the response to cancer therapy |
WO2022217878A1 (en) * | 2021-04-13 | 2022-10-20 | 广东唯泰生物科技有限公司 | Preparation method and recovery method for pariduval mesenchymal stem cells |
Also Published As
Publication number | Publication date |
---|---|
AU2005202984A1 (en) | 2005-08-04 |
AU780573B2 (en) | 2005-04-07 |
CA2406733A1 (en) | 2001-06-28 |
EP1242071A4 (en) | 2004-12-29 |
AU2439201A (en) | 2001-07-03 |
EP1242071A1 (en) | 2002-09-25 |
AU2005202984B2 (en) | 2009-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050143451A1 (en) | Use of parthenolide to inhibit cancer | |
AU2005202984B2 (en) | Use of parthenolide to inhibit cancer | |
Ren et al. | Synergistic anti-cancer effects of galangin and berberine through apoptosis induction and proliferation inhibition in oesophageal carcinoma cells | |
Kim et al. | Bergamottin, a natural furanocoumarin obtained from grapefruit juice induces chemosensitization and apoptosis through the inhibition of STAT3 signaling pathway in tumor cells | |
Pan et al. | Acacetin suppressed LPS-induced up-expression of iNOS and COX-2 in murine macrophages and TPA-induced tumor promotion in mice | |
US20080085874A1 (en) | Small molecule potentiator of hormonal therapy for breast cancer | |
Xiao et al. | z-Guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, inhibits angiogenesis in vitro and in vivo | |
US8252835B2 (en) | Compounds and methods for treating estrogen receptor-related diseases | |
De Stefano et al. | Antiproliferative and antiangiogenic effects of the benzophenanthridine alkaloid sanguinarine in melanoma | |
Luo et al. | Peiminine inhibits the IL-1β induced inflammatory response in mouse articular chondrocytes and ameliorates murine osteoarthritis | |
Pan et al. | Targeting of multiple senescence-promoting genes and signaling pathways by triptonide induces complete senescence of acute myeloid leukemia cells | |
Hu et al. | MicroRNA-23b alleviates neuroinflammation and brain injury in intracerebral hemorrhage by targeting inositol polyphosphate multikinase | |
Chen et al. | Cedrol attenuates collagen-induced arthritis in mice and modulates the inflammatory response in LPS-mediated fibroblast-like synoviocytes | |
Hao et al. | Resveratrol suppresses bone cancer pain in rats by attenuating inflammatory responses through the AMPK/Drp1 signaling | |
Chang et al. | Tannins in Terminalia bellirica inhibit hepatocellular carcinoma growth by regulating EGFR-signaling and tumor immunity | |
Shi et al. | Tangeretin suppresses osteoarthritis progression via the Nrf2/NF-κB and MAPK/NF-κB signaling pathways | |
Sun et al. | Propranolol inhibits proliferation and induces apoptosis of hemangioma-derived endothelial cells via Akt pathway by down-regulating Ang-2 expression | |
Cai et al. | Patchouli alcohol suppresses castration-resistant prostate cancer progression by inhibiting NF-κB signal pathways | |
Mahata et al. | PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer | |
Zopf et al. | Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo | |
WO2009108361A1 (en) | Methods for treatment and prevention of breast cancer | |
Xue et al. | L-Tetrahydropalmatine Inhibits the Progression of Glioblastoma Tumor by Suppressing the Extracellular-Signal-Regulated Kinase/Nuclear Factor-Kappa B Signaling Pathway. | |
Yao et al. | peptide motif Menu | |
KR102434348B1 (en) | Pharmaceutical composition for preventing or treating endometriosis comprising quercetin, luteolin, delphinidin or mixture thereof | |
KR101950386B1 (en) | Pharmaceutical composition comprising 15-keto prostaglandin e2 for treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10178054 Country of ref document: US Ref document number: 2406733 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 24392/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000988155 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000988155 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 24392/01 Country of ref document: AU |